On Monday morning, all three main stock indexes moved lower after the opening bell, pulled down by falling commodity prices, specifically oil CLG6, -3.33%
A so-called Santa Rally, which roughly spans the last five to seven days of December, is “not completely out of the question…but the oil issue remains problematic,” said David O’Malley, chief executive of Penn Mutual Asset Administration.
“It’s hard to see how stocks can move higher”, O’Malley said, with “the energy-related sectors under pressure” and with growth in the rest of the stock market “mainly driven by share buybacks throughout the year.”
Today, Shares of Chimerix, Inc. (NASDAQ:CMRX) declined -80.26% and is at $7.02 in the Real-Time trading session. The company opened at $7.85, and is moving between $6.89 - 7.90, through the day.
Chimerix, declared that its Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT) did not achieve its primary endpoint for the prevention of clinically noteworthy cytomegalovirus (CMV) infection through Week 24 after transplant.
During the on-treatment period through Week 14 after HCT, fewer patients in the brincidofovir arm had a CMV infection, consistent with the positive antiviral effect of the compound seen in the Phase 2 study. However, during the 10 weeks off treatment from Week 14 to Week 24, there was an improvement in CMV infections in the brincidofovir arm contrast to the control arm. There was also a non-statistically noteworthy improvement in mortality in the brincidofovir arm contrast to the control arm.
Preliminary analysis suggests that the primary endpoint failures in both the prevention of CMV infections and mortality in the brincidofovir arm were driven by confirmed cases of graft-as contrast to-host-disease (GVHD), which resulted in a significantly higher use of corticosteroids than in the control arm. Both GVHD and use of corticosteroids are risk factors for “late” CMV infection that occurs after discontinuation of the antiviral in HCT recipients.
Amedica Corporation (NASDAQ:AMDA) declined -1.67% right now and is at $0.1002. The 52-week range of the share price is from $0.09 - 1.12. The company has total market capitalization of $15.39M.
Shares of Pfizer Inc. (NYSE:PFE), lost -0.34%, and is now trading at $32.51. Its overall volume is 6,199,400 shares right now, and average trading volume of 36,365,900 shares.
Pfizer Inc. (NYSE: PFE) saw its short interest jump to 85.66 million shares from the previous 65.52 million. Last February, short interest spiked incredibly, and since that time it has slowly backed off. The highest short interest reading on the year was 207.4 million. Shares of Pfizer closed Thursday at $32.62, within a 52-week trading range of $28.47 to $36.46. 247wallst.com Reports
DISCLAIMER:
This article is published by www.stocksnewswire.com. The content included in this article is just for informational purposes only. Stocksnewswire.com takes sensible consideration to ensure that the data given in this article is up to date and accurate. The news, prices, opinions, research, analysis, and other information published in this article are obtained from sources believed to be reliable.
Neither Stocksnewswire.com nor any of Stocksnewswire.com partners make any representation or guarantee as to the fulfillment or precision of the information contained in this article.
Investors must consult their own additional due diligence with any potential investment or highlighted company before making any decision on behalf of information offered by Stocksnewswire.com.
Information contained in this article may contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long-term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.